当前位置: 首页 > 详情页

Navigating the future of diabetes: innovative nomogram models for predicting all-cause mortality risk in diabetic nephropathy

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Xuanwu Hosp, Dept Vasc Surg, 45 Changchun St, Beijing, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Dept Intens Care Med, Beijing, Peoples R China
出处:
ISSN:

关键词: Diabetes Diabetic nephropathy Nomogram All-cause mortality

摘要:
Objective This study aims to establish and validate a nomogram model for the all-cause mortality rate in patients with diabetic nephropathy (DN).Methods We analyzed data from the National Health and Nutrition Examination Survey (NHANES) spanning from 2007 to 2016. A random split of 7:3 was performed between the training and validation sets. Utilizing follow-up data until December 31, 2019, we examined the all-cause mortality rate. Cox regression models and Least Absolute Shrinkage and Selection Operator (LASSO) regression models were employed in the training cohort to develop a nomogram for predicting all-cause mortality in the studied population. Finally, various validation methods were employed to assess the predictive performance of the nomogram, and Decision Curve Analysis (DCA) was conducted to evaluate the clinical utility of the nomogram.Results After the results of LASSO regression models and Cox multivariate analyses, a total of 8 variables were selected, gender, age, poverty income ratio, heart failure, body mass index, albumin, blood urea nitrogen and serum uric acid. A nomogram model was built based on these predictors. The C-index values in training cohort of 3-year, 5-year, 10-year mortality rates were 0.820, 0.807, and 0.798. In the validation cohort, the C-index values of 3-year, 5-year, 10-year mortality rates were 0.773, 0.788, and 0.817, respectively. The calibration curve demonstrates satisfactory consistency between the two cohorts.Conclusion The newly developed nomogram proves to be effective in predicting the all-cause mortality risk in patients with diabetic nephropathy, and it has undergone robust internal validation.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 4 区 泌尿学与肾脏学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 泌尿学与肾脏学
JCR分区:
出版当年[2022]版:
Q3 UROLOGY & NEPHROLOGY
最新[2023]版:
Q2 UROLOGY & NEPHROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Capital Med Univ, Xuanwu Hosp, Dept Vasc Surg, 45 Changchun St, Beijing, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16399 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院